The challenges facing blood tests for cancer as Grail debuts on Nasdaq

After a decade of drama, Grail starts public trading with high hopes for its multi-cancer test — but many issues yet to settle.

June 25, 2024 Check out STAT+

Sponsored By

Grail STAT+ | Grail, aiming to market a blood test for cancer, faces host of challenges as it debuts on Nasdaq After a decade of drama, Grail starts public trading with high hopes for its multi-cancer test but also many issues yet to settle. By Matthew Herper Hank Green on his 'Pissing Out Cancer' comedy special, ulcerative colitis, and the jokes that got cut Green describes his journey with Hodgkin's lymphoma, and why he cut out some jokes from his special: 'It's hard to make pain funny.' By Brittany Trang STAT+ | House panel weighs new plan for Medicare coverage of Wegovy, cancer blood tests Medicare coverage for weight-loss drugs like Wegovy and cancer tests has broad support, but the price is likely to be high. By John Wilkerson and Rachel Cohrs Zhang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser